Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 8245003 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Marklund U, et al. (1993) Multiple signal transduction pathways induce phosphorylation of serines 16, 25, and 38 of oncoprotein 18 in T lymphocytes. J Biol Chem 268, 25671-80 8245003
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S16-p - STMN1 (human) ▲
Orthologous residues
STMN1 (human): S16‑p, STMN1 (mouse): S16‑p, STMN1 (rat): S16‑p, STMN1 (chicken): S16‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, electrophoretic mobility shift, mutation of modification site, phosphopeptide mapping
 Disease tissue studied:  lymphoma, T cell lymphoma
 Relevant cell lines - cell types - tissues:  EL-4 (T lymphocyte), Jurkat (T lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE PKACa (cow)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ionomycin increase
anti-CD3 increase
herbimycin A anti-CD3 inhibit treatment-induced increase

S25-p - STMN1 (human) ▲
Orthologous residues
STMN1 (human): S25‑p, STMN1 (mouse): S25‑p, STMN1 (rat): S25‑p, STMN1 (chicken): G25‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, electrophoretic mobility shift, mutation of modification site, phosphopeptide mapping
 Disease tissue studied:  lymphoma, T cell lymphoma
 Relevant cell lines - cell types - tissues:  EL-4 (T lymphocyte), Jurkat (T lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE ERK1 (human)
 Comments:  sea star kinase
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
Ro31-7549 phorbol ester inhibit treatment-induced increase

S38-p - STMN1 (human) ▲
Orthologous residues
STMN1 (human): S38‑p, STMN1 (mouse): S38‑p, STMN1 (rat): S38‑p, STMN1 (chicken): S38‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, electrophoretic mobility shift, mutation of modification site, phosphopeptide mapping
 Disease tissue studied:  lymphoma, T cell lymphoma
 Relevant cell lines - cell types - tissues:  EL-4 (T lymphocyte), Jurkat (T lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE ERK1 (human)
 Comments:  sea star kinase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.